Stockscreener 앱 받기
40.84
0.01%
-0.005
시간 외 거래:
40.83
-0.015
-0.04%
전일 마감가:
$40.85
열려 있는:
$40.85
하루 거래량:
2.50M
Relative Volume:
0.50
시가총액:
$5.22B
수익:
$1.00B
순이익/손실:
$22.39M
주가수익비율:
330.73
EPS:
0.1235
순현금흐름:
$45.01M
1주 성능:
+0.38%
1개월 성능:
+115.65%
6개월 성능:
+61.95%
1년 성능:
+115.31%
1일 변동 폭
$40.83
$40.88
1주일 범위
$40.64
$40.88
52주 변동 폭
$16.10
$40.88
아펠리스 Stock (APLS) Company Profile
명칭
Apellis Pharmaceuticals Inc
전화
617-977-5700
주소
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
40.84 | 5.22B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
아펠리스 Stock (APLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 개시 | Roth Capital | Buy |
| 2026-01-28 | 개시 | Barclays | Equal Weight |
| 2026-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-06 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-15 | 개시 | Wells Fargo | Overweight |
| 2025-09-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-05-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-17 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-11-21 | 개시 | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-16 | 개시 | William Blair | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Neutral |
| 2024-02-05 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-12-14 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-02 | 개시 | Mizuho | Neutral |
| 2023-10-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-15 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 재확인 | Citigroup | Buy |
| 2023-08-03 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-08-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-19 | 개시 | H.C. Wainwright | Buy |
| 2022-06-17 | 재개 | Stifel | Buy |
| 2022-04-14 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 재확인 | BMO Capital Markets | Outperform |
| 2021-09-10 | 재확인 | Credit Suisse | Neutral |
| 2021-09-10 | 재확인 | Needham | Buy |
| 2021-09-10 | 재확인 | Oppenheimer | Outperform |
| 2021-09-10 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-08-19 | 개시 | Jefferies | Buy |
| 2021-08-19 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2020-11-19 | 개시 | Needham | Buy |
| 2020-09-01 | 개시 | Stifel | Buy |
| 2020-07-20 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-04-01 | 개시 | Raymond James | Strong Buy |
| 2020-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-11 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2020-01-07 | 개시 | SVB Leerink | Mkt Perform |
| 2019-12-19 | 개시 | BofA/Merrill | Buy |
| 2019-11-22 | 개시 | Wedbush | Underperform |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-08-01 | 재확인 | Cantor Fitzgerald | Overweight |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 개시 | Robert W. Baird | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-07-30 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-04-12 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
아펠리스 주식(APLS)의 최신 뉴스
Mizuho reiterates Apellis stock rating citing M&A process details - Investing.com
Mizuho reiterates Apellis stock rating citing M&A process details By Investing.com - Investing.com Canada
Biogen raised to overweight at Piper Sandler on Apellis buyout - MSN
Biogen to acquire Apellis for $5.6B to strengthen immunology portfolio - MSN
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD - Investing.com
Apellis Pharmaceuticals stock hits 52-week high at 40.87 USD By Investing.com - Investing.com UK
M&A Class Action Firm Investigating Multiple Mergers - National Today
Biogen stock upgraded at Piper Sandler (BIIB:NASDAQ) - Seeking Alpha
Apellis (APLS) board recommends $41 cash takeover by Biogen with up to $4 CVR - Stock Titan
Biogen (NASDAQ: APLS) bids $41 per share plus up to $4 CVR for Apellis - Stock Titan
Wellington Management Group LLP Significantly Reduces Stake in Apellis Pharmaceuticals Inc - GuruFocus
Support Test: Can Apellis Pharmaceuticals Inc stock outperform in a bear marketMarket Weekly Review & Precise Buy Zone Tips - baoquankhu1.vn
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Valuation Update: Does Apellis Pharmaceuticals Inc stock have upside surprise potential - baoquankhu1.vn
Biogen lands two fast-growing drugs in blockbuster Apellis deal - MSN
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Sahm
US Market Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsQuarterly Portfolio Report & High Return Trade Guides - baoquankhu1.vn
Apellis (APLS) director shifts 5,750 trust shares to spouse account - Stock Titan
Apellis Stock More Than Doubles on Biogen News. Here’s What to Know. - Barron's
Trading the Move, Not the Narrative: (APLS) Edition - Stock Traders Daily
Biogen’s Apellis Deal And High Dose SPINRAZA Shift Growth Outlook - Sahm
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Apellis Pharmaceuticals Stock Rockets 140% With 6-Day Winning Streak - Trefis
6-Day Rally Sends Apellis Pharmaceuticals Stock Up 140% - Trefis
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 By Investing.com - Investing.com Australia
Biogen (NASDAQ: APLS) readies tender offer for Apellis under March 31, 2026 deal - Stock Titan
Apellis Pharmaceuticals stock reaches 52-week high at $40.71 - Investing.com
Retail Surge: Can Apellis Pharmaceuticals Inc grow without dilution2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn
RBC Adjusts Price Target on Apellis Pharmaceuticals to $41 From $21, Maintains Sector Perform Rating - marketscreener.com
Biogen Taps Alloy Platform To Push Antisense Drug Pipeline Forward - Benzinga
Apellis Pharmaceuticals Acquisition Under Investigation - National Today
Wellington files 13G/A owning 249,635 shares of Apellis (APLS) - Stock Titan
Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a ... - Bluefield Daily Telegraph
Shareholder Alert: Ademi LLP investigates whether Apellis - GlobeNewswire
5-Day Rally Sends Apellis Pharmaceuticals Stock Up 139% - Trefis
Apellis Pharmaceuticals Stock Surges 139%, With A 5-Day Winning Spree - Trefis
Biogen (NASDAQ: APLS) files Form 3 on Apellis voting group status - Stock Titan
Biogen Discloses Tender Offer at Apellis with 14.2% Stake - TradingView — Track All Markets
[SCHEDULE 13D] Apellis Pharmaceuticals, Inc. Major Shareholder Acquisition (>5%) - Stock Titan
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology - FinancialContent
Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Biogen Paid a 140% Premium for Apellis. Was the $5.6B Deal Worth It? - TIKR.com
Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get - Benzinga
Apellis Pharmaceuticals, Inc. (APLS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Apellis surges on $5.6B buyout deal with Biogen - MSN
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
TD Cowen Maintains Apellis Pharmaceuticals (APLS) Buy Recommendation - MSN
APLS PE Ratio & Valuation, Is APLS Overvalued - Intellectia AI
Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - Medical Dialogues
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
아펠리스 (APLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):